tiprankstipranks
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
US Market

Diamedica Therapeutics (DMAC) Income Statement

Compare
490 Followers

Diamedica Therapeutics Income Statement

Last quarter (Q3 2024), Diamedica Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Diamedica Therapeutics's net income was $-6.27M. See Diamedica Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ -30.00K$ -25.00K$ -24.00K$ -21.00K
Operating Expenses
$ 26.68M$ 21.27M$ 14.00M$ 13.65M$ 12.49M
Depreciation and Amortization
$ 0.00$ 30.00K$ 25.00K$ 24.00K$ 21.00K
EBITDA
$ 0.00$ -19.31M$ -13.98M$ -13.62M$ -12.24M
Operating Income
$ 0.00$ -21.27M$ -14.00M$ -13.65M$ -12.70M
Other Income/Expenses
$ 0.00$ 1.93M$ 353.00K$ 82.00K$ 434.00K
Pretax Income
$ -24.41M$ -19.34M$ -13.65M$ -13.56M$ -12.27M
Net Income
$ -24.44M$ -19.38M$ -13.68M$ -13.59M$ -12.29M
Per Share Metrics
Basic EPS
$ -0.60$ -0.60$ -0.52$ -0.65$ -0.78
Diluted EPS
$ -0.60$ -0.60$ -0.52$ -0.65$ -0.78
Weighted Average Shares Outstanding
40.40M 32.57M 26.44M 20.77M 15.68M
Weighted Average Shares Outstanding (Diluted)
40.40M 32.57M 26.44M 20.77M 15.68M
Currency in USD

Diamedica Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis